These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23811836)

  • 1. Erythropoietin in cardiac disease: effective or harmful?
    Mastromarino V; Musumeci MB; Conti E; Tocci G; Volpe M
    J Cardiovasc Med (Hagerstown); 2013 Dec; 14(12):870-8. PubMed ID: 23811836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin and the heart: facts and perspectives.
    Mastromarino V; Volpe M; Musumeci MB; Autore C; Conti E
    Clin Sci (Lond); 2011 Jan; 120(2):51-63. PubMed ID: 20929439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin and the vascular wall: the controversy continues.
    Jelkmann W; Elliott S
    Nutr Metab Cardiovasc Dis; 2013 Dec; 23 Suppl 1():S37-43. PubMed ID: 22682530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin: new horizon in cardiovascular medicine.
    Koul D; Dhar S; Chen-Scarabelli C; Guglin M; Scarabelli TM
    Recent Pat Cardiovasc Drug Discov; 2007 Jan; 2(1):5-12. PubMed ID: 18221097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit.
    Lipsic E; Westenbrink BD; van der Meer P; van der Harst P; Voors AA; van Veldhuisen DJ; Schoemaker RG; van Gilst WH
    Eur J Heart Fail; 2008 Jan; 10(1):22-9. PubMed ID: 18077209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoietin treatment in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials.
    Gao D; Ning N; Niu X; Dang Y; Dong X; Wei J; Zhu C
    Am Heart J; 2012 Nov; 164(5):715-727.e1. PubMed ID: 23137502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin derivate improves left ventricular systolic performance and attenuates left ventricular remodeling in rats with myocardial infarct-induced heart failure.
    Xu K; George I; Klotz S; Hay I; Xydas S; Zhang G; Cerami A; Wang J
    J Cardiovasc Pharmacol; 2010 Nov; 56(5):506-12. PubMed ID: 20881614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the role of erythropoietin in acute myocardial infarct? Bridging the gap between experimental models and clinical trials.
    Roubille F; Prunier F; Barrère-Lemaire S; Leclercq F; Piot C; Kritikou EA; Rhéaume E; Busseuil D; Tardif JC
    Cardiovasc Drugs Ther; 2013 Aug; 27(4):315-31. PubMed ID: 23695774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction.
    van der Meer P; Lipsic E; Henning RH; Boddeus K; van der Velden J; Voors AA; van Veldhuisen DJ; van Gilst WH; Schoemaker RG
    J Am Coll Cardiol; 2005 Jul; 46(1):125-33. PubMed ID: 15992646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoiesis stimulation in acute ischemic syndromes.
    Ruifrok WP; Lipsic E; de Boer RA; van Gilst WH; van Veldhuisen DJ
    Heart Fail Clin; 2010 Jul; 6(3):313-21. PubMed ID: 20630406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular effects of erythropoietin: anemia and beyond.
    Guglin ME; Koul D
    Cardiol Rev; 2006; 14(4):200-4. PubMed ID: 16788333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin and the heart: physiological effects and the therapeutic perspective.
    Sanchis-Gomar F; Garcia-Gimenez JL; Pareja-Galeano H; Romagnoli M; Perez-Quilis C; Lippi G
    Int J Cardiol; 2014 Feb; 171(2):116-25. PubMed ID: 24377712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of erythropoiesis-stimulating agents in acute ST-segment elevation myocardial infarction: a systematic review.
    Li J; Xu H; Gao Q; Wen Y
    Eur J Clin Pharmacol; 2012 May; 68(5):469-77. PubMed ID: 22086550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure.
    Westenbrink BD; Ruifrok WP; Voors AA; Tilton RG; van Veldhuisen DJ; Schoemaker RG; van Gilst WH; de Boer RA
    Cardiovasc Res; 2010 Jul; 87(1):30-9. PubMed ID: 20139114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential role of erythropoietin in chronic heart failure: from the correction of anemia to improved perfusion and reduced apoptosis?
    Timmer SA; De Boer K; Knaapen P; Götte MJ; Van Rossum AC
    J Card Fail; 2009 May; 15(4):353-61. PubMed ID: 19398085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside.
    Lipsic E; Schoemaker RG; van der Meer P; Voors AA; van Veldhuisen DJ; van Gilst WH
    J Am Coll Cardiol; 2006 Dec; 48(11):2161-7. PubMed ID: 17161240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential of erythropoietin for conferring cardioprotection complementing reperfusion.
    Binbrek AS; Mittal B; Rao KN; Sobel BE
    Coron Artery Dis; 2007 Nov; 18(7):583-5. PubMed ID: 17925614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Erythropoietin: a new perspective in cardiovascular therapy].
    Raddino R; Robba D; Caretta G; Bonadei I; Teli M; Zanini G; Madureri A; Vizzardi E; Dei Cas L
    Monaldi Arch Chest Dis; 2008 Dec; 70(4):206-13. PubMed ID: 19263796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial.
    Prunier F; Bière L; Gilard M; Boschat J; Mouquet F; Bauchart JJ; Charbonnier B; Genée O; Guérin P; Warin-Fresse K; Durand E; Lafont A; Christiaens L; Abi-Khalil W; Delépine S; Benard T; Furber A
    Am Heart J; 2012 Feb; 163(2):200-7.e1. PubMed ID: 22305837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current perspectives on protective roles of erythropoietin in cardiovascular system: erythropoietin receptor as a novel therapeutic target.
    Kagaya Y; Asaumi Y; Wang W; Takeda M; Nakano M; Satoh K; Fukumoto Y; Shimokawa H
    Tohoku J Exp Med; 2012 Jun; 227(2):83-91. PubMed ID: 22688525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.